Glaucoma

Higher IOP may be a predictable marker of cardiovascular disease (CVD) in some individuals, according to a study from South Korea.

iSTAR Medical SA announced that the first patient in its European multicentre clinical trial has been successfully implanted with the company's STARflo glaucoma drainage device.

A preservative-free IOP-lowering eye drop that is a combination of tafluprost and timolol (Taptiqom, Santen) is seeking national licences in European countries after a positive decentralized procedure and a final assessment report from reference member state Germany, the Federal Institute for Drugs and Medical Devices of Germany, and agreement by concerned member states that the fixed-dose product is approvable.

Travoprost monotherapy has demonstrated long-term 24-hour efficacy for the treatment of primary open-angle glaucoma (POAG).

Anti-glaucoma preparations that do not contain benzalkonium chloride (BAK) were associated with a change in lubricant use in a study of 240 glaucoma patients, suggesting reduction in some ocular surface disease symptoms, according to research published online.

Endoscopic cyclophotocoagulation (ECP) and phacoemulsification cataract extraction, when combined, result in greater reduction of IOP and need for IOP-lowering medications over 3 years compared with cataract extraction by itself.

An international study led by King's College London has identified genetic links to glaucoma.

Severe obstructive sleep apnoea (OSA) is an important risk factor for developing glaucoma and must be treated in those who have it to improve control of the eye disease, according to new research.

In this article, comparative data is presented proving that trabeculectomy is more effective than non-penetrating options, however, does pose an increased risk of complications, leading to the conclusion that at the moment, procedures should be chosen on an individual basis.

Glaucomatous structural damage may affect an individual's ability to divide attention when performing daily tasks such as driving, according to research recently published online.

A fixed combination of brinzolamide 1% and brimonidine 0.2% used twice a day lowers IOP significantly more than either drug alone and is as safe as either, according to results of a 6-month, Phase III study.

The European Commission has approved the eye drop suspension of brinzolamide 10 mg/mL and brimonidine tartrate 2 mg/mL to decrease elevated intraocular pressure (IOP) in adult patients who have open-angle glaucoma or ocular hypertension.

Acute glaucoma in mice is largely an inflammatory disease, and high intraocular pressure (IOP) causes vision loss by starting an inflammatory response similar to that caused by bacterial infections.

When detecting and evaluating the progression of glaucoma, Bruch's membrane opening-minimum rim width (BRO-MRW) may be the best predictor of the threshold of visual sensitivity and total deviation of visual field, according to a new study.

Diurnal IOP curves have limited value in clinical practice for patients with primary open-angle glaucoma (POAG), according to a newly published study.

Gonioscopy-assisted transluminal trabeculotomy is a circumferential trabeculotomy performed via a minimally invasive, ab interno approach. Results from follow-up of 6 to 12 months in a series of 85 adult eyes with uncontrolled glaucoma show high IOP lowering, along with a reduced need for medication.

When people sleep with their heads elevated 20 degrees, their nocturnal IOP is lower than when they sleep with their heads flat, finds a newly published study.

Increased blood pressure contributes to elevated IOP and possibly the development of glaucoma, according to the findings of a recent meta-analysis.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for brinzolamide 10 mg/mL and brimonidine tartrate 2 mg/mL eye drops suspension (Simbrinza, Alcon) to decrease elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension, for whom monotherapy provides insufficient IOP reduction.

Implantation of two trabecular micro-bypass devices (iStent inject, Glaukos) reduced intraocular pressure (IOP) at least as effectively as a fixed combination of latanoprost/timolol in patients who had open-angle glaucoma that was not controlled by one medication, according to a recent study.

Prof. Iester describes his recent study investigating whether the addition of a tear substitute would protect exposed corneal epithelial cells from damage.

A Phase II dose-ranging study has been initiated for Amakem Therapeutics? glaucoma drug candidate AMA0076, a highly potent, locally acting Rho Kinase (ROCK) inhibitor designed to reduce intraocular pressure (IOP) while minimizing common ROCK inhibitor side effects such as hyperaemia.

A supracilliary micro-stent, when implanted in conjunction with cataract surgery, substantially reduces intraocular pressure (IOP) with minimal complications in patients with open-angle glaucoma, according to researchers in Germany and the US.

Patients with refractory glaucoma in whom a proprietary glaucoma implant was placed needed significantly less adjunctive medication to experience success in treatment compared with those who received a proprietary glaucoma valve. However, fewer of those in the latter group had serious postoperative complications, according to recently published 3-year outcomes.

In this article, the authors describe their novel technique for penetrative trabeculectomy in primary open-angle glaucoma patients, called sutureless trabeculectomy.

Preservatives are an important component of topical multidose glaucoma medications. However, many glaucoma patients have symptoms of ocular surface disease (OSD), which can affect quality of life, treatment adherence and surgical outcomes. In this article, Prof. Baudouin offers straightforward steps to assess OSD and identify the patients most at risk.

The authors have sought to expand the concept of automated alternation flicker to improve detection of glaucomatous optic neuropathy and highlight their findings in this article.

Carbon dioxide laser assisted sclerectomy surgery (CLASS) is being used as an effective and safe, minimally invasive treatment for glaucoma. In this article, two surgeons at the forefront of research, development and implementation of this approach discuss this surgical option and its benefits for the ophthalmic market.

The combination of microinvasive glaucoma surgeries with cataract surgery may address a patient's cataract and glaucoma in one procedure.

Ultrasound circular cyclocoagulation is a non-invasive treatment for refractory glaucoma that is approved in Europe.